Company Adds Significant Capacity to Prepare For Surge in Outbound Volume
Research Triangle Park, North Carolina, May 4, 2016, Marken announced today that they have expanded their network of qualified third party service providers and customs brokers to reinforce the company’s infrastructure and prepare for a significant increase in drug, vaccine, API and ancillary shipment volume. The company is investing ahead of the market and reinforcing the increased regulatory requirements in many countries. New providers have been qualified in the United States, Ukraine, Russia, Italy, Peru and Brazil. This comes after significant changes were made in 2015 in Mexico, Taiwan, Japan and China. The company has also increased warehouse and storage capacity in Frankfurt, Brussels, and Zurich and has completed a consolidation of its operations at John F. Kennedy airport in January. All of these actions are needed to prepare for the rapid increase in volume and shipment complexity expected in the coming months.
“We are excited to announce the strengthening of our worldwide logistics network”, said Wes Wheeler, Marken’s Chief Executive Officer, “The market is growing and we are growing with it. The rapid increase in the use of biologic drug and temperature-sensitive products, cell & gene therapies and direct to patient logistic demands from clients are providing us a unique opportunity to qualify new service providers and enforce our stringent GDP requirements on our network. At the same time, we are expanding our warehouse capacity in cities where we see demand and are staying ahead of the curve. Our focus will always be on the client and their needs, and to remain flexible in all circumstances.”
Recent fresh data from VisionGain, an independent London-based research firm, indicates that the clinical cold chain logistics market was $1.56 billion in 2015 and is expected to grow at a compound annual growth rate of 8.1% through 2019. The broader clinical trial logistics market, including all services, was $4 billion. Nearly one third of all drugs in development are associated with biologic material and three-fourths of these products are temperature controlled. The rapid increase in cold chain logistics is driven by these biologic drugs, but also increased globalization of clinical trials and evolving technology which enables global transportation and increased regulation.
Marken is the only patient-centric supply chain organization 100% dedicated to the pharmaceutical and life sciences industries. Marken maintains the leading position for Direct to Patient services and biological sample shipments, and offers a state of the art GMP-compliant depot network and logistic hubs in 43 locations worldwide. Marken’s 630 staff members manage 50,000 drug and biological shipments every month at all temperature ranges in more than 150 countries. Additional services such as biological kit production, ancillary material sourcing, storage and distribution, shipment lane verification and qualifications, as well as GDP, regulatory and compliance consultancy add to Marken’s unique position in the pharma and logistics industry.
CONTACT: Christine Noble, email@example.com, +1 919 474 6890, www.marken.com